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Allocating just 1%–2% of Global Health
Initiative funds to conduct research and
development for neglected tropical diseases
drugs, vaccines, and diagnostics would
create a new generation of tools to eliminate
our planet’s greatest scourges and help
shape United States foreign policy.
On May 5, 2009, the Obama Adminis-
tration announced its intention to launch an
ambitious United States governmental strat-
egy for global health [1–3]. The US Global
Health Initiative (GHI) proposes US$63
billion over 6 years (FY 2009–FY 2014),
US$10.5 billion annually on average, ap-
proximately 70% of which would be spent
on the US President’s Emergency Plan for
AIDS Relief (PEPFAR) [1]. If appropriated
each year by Congress, the GHI would
represent a significant response to calls by the
Institute of Medicine of the National Acad-
emies for the US government (USG) to
invest US$15 billion annually on develop-
ment assistance for global health by 2012 [3].
In its current form, most of GHI is
devoted to direct implementation of exist-
ing treatments and preventive interventions
for the ‘‘big three diseases,’’ i.e., HIV/
AIDS, malaria, and tuberculosis, especially
the delivery of antiretroviral drugs and
other prevention measures, antimalarial
drugs and bednets, and direct observed
therapy, respectively, as well as other
critical interventions to improve maternal
and child health and strengthen health
systems [1,3]. There is also an unprece-
dented commitment to provide treatments
for the neglected tropical diseases (NTDs),
with US$65 million committed in FY2010
for rapid impact packages and related
measures targeting the seven most common
NTDs, which comprise the most prevalent
infections affecting the world’s poor [4–8].
The US Commitment to
Neglected Diseases R&D
GHI is already making a huge difference
in the lives of the world’s 1.4 billion poorest
people in developing countries who live
below the World Bank poverty figure of
US$1.25 per day—a group sometimes
referred to as the ‘‘bottom billion’’ [4].
However, currently GHI largely fails to
address research and development (R&D)
needs for the manufacture and testing of a
new generation of global health products,
i.e., new drugs, vaccines, diagnostics, and
other tools, for neglected diseases, defined
broadly here to include both the big three
diseases and the NTDs [9]. To be sure,
outside of GHI, the USG’s overall invest-
ment in neglected diseases runs deep [9].
According to the 2009 G-FINDER (Global
Funding of Innovation for Neglected Diseas-
es) report in 2008, the USG provided almost
three-quarters of all global public spending
on neglected diseases, with an estimated
approximate investment of US$1.25 billion
[3,9]. Approximately 86% (US$1.08 billion)
of those funds came from the National
Institutes of Health (NIH) and most of that
from the National Institute of Allergy and
Infectious Diseases (NIAID), with 80% of the
NIAID funds committed for the big three
diseases [9]. NIH-NIAID currently provides
intramural support for the Dale and Betty
Bumpers Vaccine Research Center (VRC),
whose primary mission is to develop global
HIV/AIDS vaccines [10], and the Labora-
tory of Malaria Immunology and Vaccinol-
ogy [11], as well as substantial extramural
support to universities and private research
institutes to support basic research, the
development of new drugs to overcome
resistance [12–15], and some vaccine re-
search. In addition, the United States
Agency for International Development
(USAID) provides substantial resources to
support vaccine development for HIV/
AIDS through the International AIDS
Vaccine Initiative, a non-profit product
development partnership (PDP) [16], and
for malaria vaccine development in collab-
oration with the Walter Reed Army Institute
for Research [17].
In 2008, over 60 ministers of health,
science, technology, and education met in
Bamako, Mali, for a Global Ministerial
Forum on Research for Health [18]. The
resulting call to action asked countries to
commit themselves to allocate at least 2% of
national health budgets to research, while
f u n d e r ss u c ha st h eU S Gw e r ea s k e dt oi n v e s t
at least 5% of health sector aid for research
[18]. The research funds provided by NIH
alone (and indeed just NIAID commitment)
are sufficient to meet the challenge laid out in
Mali, and altogether the USG has spent
US$1.25billionannuallyon neglecteddisease
research, the equivalent of approximately
12% of funds spent annually on GHI.
R&D Targeted Specifically for
the NTDs
A closer analysis of the USG’s commit-
ment to global health research reveals that
only a very small percentage of funds for
R&D were spent on the NTDs, with
minimal support for the PDPs that pro-
duce new products for these conditions.
Thus, while the USG invests heavily for
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gap for NTD product support. Why is this
significant?
The NTDs are primarily parasitic and
bacterial infections, which together with
dengue fever represent the most common
conditions of the bottom billion [4–6]. The
seven most common NTDs include the
three major soil-transmitted helminthia-
ses—ascariasis, hookworm infection, and
trichuriasis (600–800 million cases for each
helminth infection worldwide)—followed
by schistosomiasis (200–600 million infec-
tions), lymphatic filariasis (120 million),
trachoma (40 million), and onchocerciasis
(20–40 million), followed by liver fluke
infection (20 million), leishmaniasis (12
million), and Chagas disease (8–9 million)
[19–22]. However, an unknown number of
people, possibly as many as 50 million, may
also be infected with amebiasis and dengue
fever [23,24]. Practically speaking, these
huge numbers mean that virtually all of the
bottom billion, i.e., all of the world’s poor,
suffers from at least one NTD. Moreover,
the disabling effects of NTDs in children,
pregnant women, and agricultural workers
have been shown to produce a profound
economic impact that actually traps the
bottom billion in poverty [7,19].
While the USG (through the NIH) and
the major pharmaceutical companies are
engaged in a global enterprise for devel-
oping new drugs and vaccines for HIV/
AIDS, malaria, and tuberculosis, by com-
parison NTD product development is
being neglected [6]. A list of the most
urgently needed new control tools for the
NTDs was highlighted previously [6]. The
priority list includes safer and more
effective drugs for kinetoplastid infections,
such as Chagas disease, leishmaniasis, and
human African trypanosomiasis; a macro-
filaricide drug; and new vaccines to
combat leishmaniasis, Chagas disease,
hookworm infection, schistosomiasis, den-
gue, and enteric bacterial pathogens [6].
Such biotechnologies have been referred
to as ‘‘antipoverty vaccines,’’ a term that
reflects the reality that most of the NTDs
actually cause poverty because of their
adverse impact on child development and
cognition and worker productivity. Thus,
NTD vaccines (and presumably drugs and
diagnostics as well) represent critical inter-
ventions for promoting economic develop-
ment as well as health in low-income
countries [4,7,8]. A more complete list of
needed antipoverty technologies is provid-
ed in Table 1 [6,9].
Because the NTDs occur almost exclu-
sively among the bottom billion, most of
the antipoverty technologies have no
commercial value even though they offer
the promise of tremendous public health
benefit [6–9]. It follows that in the absence
of substantial financial returns, with a few
exceptions (such as the development of a
vaccine for dengue, which also has a
potential market for Singapore, the Gulf
Coast of the United States, and the
wealthier Brazilian coastal cities, for ex-
ample), most of the major pharmaceutical
companies have not embarked on sub-
stantial R&D programs for NTD prod-
ucts. Instead, today many of the antipov-
erty technologies are being developed by
PDPs, i.e., non-profit organizations that
employ industrial business practices in
order to develop new technologies for
neglected diseases [25], together with
scientific R&D institutes and organizations
in disease-endemic countries. Today, the
PDPs depend on support from European
governments in addition to substantial
funds from the Bill & Melinda Gates
Foundation [25], with comparatively mod-
est support from the USG.
Thus, while the NIH is a significant
contributor to global health research, the
agency spends a high percentage of its
funds on the big three diseases, with less
than 10% of its overall neglected disease
research budget to fund the most common
NTDs, including the kinetoplastid infec-
tions ($49 million), dengue ($27 million),
and all of the helminth infections ($23
million). Moreover, most of these NIH
funds are allocated to basic research and
not product development. In addition,
USAID provides no funds for PDPs
committed to the NTDs. This situation
has started to turn around with a new
effort by NIAID to fund PDPs [26],
together with two decades of support for
overseas Tropical Medicine Research
Centers [27], but overall the USG, and
USAID in particular, has not made major
commitments to PDPs for NTD product
development and clinical trials. In con-
trast, several European governments, in-
cluding the British Department for Inter-
national Development [28] and the Dutch
Ministry of Foreign Affairs [29], have
recently committed substantial PDP sup-
port, as well as the Brazilian Ministry of
Health, which now supports PDPs for
NTDs [30].
Overall, it has been estimated that
approximately US$1 billion per year over
the next 10 years will be required to put
experimental treatments and vaccines in
the PDP pipeline through large human
trials and file them with regulators [31].
Other unpublished estimates have quoted
considerably higher dollar amounts. Ulti-
mately, a significant portion of this level of
support could be provided by the USG, as
well as European governments and the
European Commission, and even some
emerging market economies [32]. The
Institute of Medicine of the National
Academies 2009 report, The U.S. Commit-
ment to Global Health: Recommendations for the
Public and Private Sectors, specifically recom-
mended support for PDPs committed to
developing novel global health technolo-
gies and interventions [3].
R&D for Vaccine Diplomacy
There are several important reasons
why the USG should support NTD
product development and testing by pro-
viding funds for both PDPs and for science
and technology agencies of NTD-endemic
countries. These activities are consistent
with our nation’s humanitarian principles
because there is a key human rights
dimension to NTD mitigation [33]. It
has been previously argued that just as the
world’s poorest people have a fundamental
right to have access to essential medicines,
they also have rights to biomedical inno-
vation [6]. But even beyond this human-
itarian rationale there is an equally
important element of enlightened self-
interest for the USG and other govern-
ments to invest in R&D for antipoverty
technologies.
The control and elimination of the
NTDs potentially has US foreign policy
implications. Most of the world’s NTDs
are believed to occur in areas of greatest
US geopolitical interests [5]. The most
heavily affected nations include those
comprising the Organisation of the Islamic
Conference, as some of the worst affected
nations include the poorest Islamic coun-
tries, such as Indonesia, Bangladesh,
Sudan, Mali, and Chad [34]; they also
include powerful middle-income nations
with nuclear weapons capabilities such as
India, Pakistan, Iran, and North Korea
[35]. Additionally, a further relationship
has been noted between nations with
NTDs and conflict such that the countries
with the highest prevalence of NTDs are
the most likely to have been engaged in
war over the last two decades [36]. Indeed,
the links between geopolitical interests,
conflict, and neglected diseases provide a
rationale for launching the GHI under the
auspices of USAID and the Department of
State, rather than through the NIH, CDC,
or other agencies of the Department of
Health and Human Services.
Because the NTDs have such a major
geopolitical dimension, R&D for new
antipoverty vaccines and drugs may there-
fore represent more than simply promot-
ing new technologies for improving health.
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erty technologies could emerge as power-
ful new interventions to enhance US
foreign policy. I have used the term
‘‘vaccine diplomacy’’ to describe joint
R&D activities between nations, especially
those with major ideological differences
[37–40]. This concept arises in part from
an interesting Cold War history that led to
the joint US–Soviet development of the
oral polio vaccine [37–40]. With this
paradigm in mind, could GHI funds be
spent in order for American scientists to
conduct similar science and technology
diplomacy with selected middle-income
Table 1. New products required or under development for the major NTDs.
a
Disease New Drugs New Vaccines New Diagnostics
New Vector Control Products or Zoonotic
Animal Reservoir Products to Block
Transmission to Humans
Protozoan NTDs
Amebiasis 2 ++ 2
Balantidiasis 22 2 2
Chagas disease ++ + +
Giardiasis 22 + 2
Hum. African trypanosomiasis ++ + +
Leishmaniasis ++ + +
Heliminth NTDs
Taeniasis-cysticercosis + 2 ++
Dracunculiasis 22 2 2
Echinococcosis + 2 ++
Food-borne trematodiases ++ + +
Loiasis + 2 + 2
Lymphatic filariasis + 2 ++
Onchocerciasis ++ + +
Schistosomiasis ++ + +
Ascariasis 22 ++
Hookworm ++ + 2
Trichuriasis + 2 + 2
Strongyloidiasis ++ + 2
Toxocariasis + 2 ++
Viral NTDs
Dengue and other flaviviruses ++ + +
Rabies ++ + +
Rift Valley fever ++ + +
Bacterial NTDs
Baronellosis + 2 + 2
Bovine tuberculosis ++ + +
Buruli ulcer ++ + 2
Cholera ++ + 2
Enteric pathogens (Gram neg) ++ + 2
Leprosy ++ + 2
Leptospirosis ++ + 2
Rheumatic fever 2 + 22
Trachoma 2 ++ 2
Treponematoses ++ + 2
Fungal NTDs
Mycetoma + 2 + 2
Paracoccidiomycosis ++ 22
Ectoparasitic infections + 2 + 2
aList of NTDs modified from http://www.plosntds.org/static/scope.action.
+, New product needed or under development; 2, new product not required or need not yet determined, based on information compiled from [6,9], and the additional
opinions of the author.
doi:10.1371/journal.pntd.0001133.t001
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vative developing countries, specifically
those with both high rates of NTDs and
a sophisticated infrastructure for conduct-
ing scientific R&D [39–41]?
Concluding Remarks
Setting aside approximately 1%–2% of
the GHI (roughly US $100–200 million
annually) for R&D on new antipoverty
vaccines and drugs would dramatically
increase the current support for new NTD
antipoverty technologies, and simulta-
neously provide capacity building activities
for key disease-endemic countries of stra-
tegic interest to the US. It could also
provide a new and exciting role for PDPs
committed to the NTDs, many of which
are US based, to engage in vaccine
diplomacy, and ultimately lead to the
development of a new generation of
poverty-reducing biotechnologies. The
mechanisms by which funds are distribut-
ed could require the establishment of peer-
reviewed study sections, possibly not too
dissimilar to those established by the NIH
in order to ensure that only the best
science is funded, and in addition there
could be specific requirements and over-
sight to place the science in a diplomatic
context. There are also opportunities to
bring in key international agencies and
organizations, including WHO-TDR, the
Special Programme for Research and
Training in Tropical Diseases [42], and
IVI, the International Vaccine Institute
based in Korea and supported in part by
the United Nations Development Program
[43]. Such science and technology diplo-
matic outreach could lead to new peace-
time roles for foreign scientists currently
engaged in nuclear weapons development,
meet President Obama’s 2009 challenge in
Cairo when he called on the US to reach
out to the Islamic world [44], and
simultaneously create a new dimension in
US foreign policy that also plays to
America’s great strengths and intellectual
prowess in biomedical R&D.
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